公开(公告)号：EP1252162B1

公开(公告)日：2012-07-25

申请号：EP01942625.3

申请日：2001-01-16

申请人： Merck Sharp & Dohme Corp.

发明人： DUGGAN, Mark, E. ,  HALCZENKO, Wasyl ,  HUTCHINSON, John, H. ,  LI, Aiwen ,  MEISSNER, Robert, S. ,  PERKINS, James, J. ,  STEELE, Thomas, G. ,  WANG, Jiabing ,  PATANE, Michael, A.

IPC分类号： A61K31/444 ,  A61K31/4166 ,  A61P19/10 ,  A61K31/4178 ,  C07D471/04 ,  C07D401/14 ,  C07D405/14 ,  C07D471/10

CPC分类号： C07D213/73 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D471/10

摘要： The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as αν integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.